Background: Published data have shown
that microRNAs (miRNAs) could play a potential role as diagnostic and
prognostic indicators in cancers. Data for the predictive value of miRNA let-7,
miR-21, and miR-205 are inconclusive. The aim of the present analysis was
therefore to evaluate the expression and the prognostic role of the above
mentioned miRNAs in early-stage (T1N0) NSCLC patients. Methods: Quantification
of let-7g, miR-21, and miR-205 expression was carried out into 105 early-stage
NSCLC by quantitative Real Time-PCR (qRT-PCR). Results: a significant association
between the low miR-205 expression and ADC histotype (p < 0.0001) compared to SCC was
found; moreover, survival analysis showed thattumors with a high miR-205 expression had a significantly
shorter mean PFS and OS compared to the patients with a low expression of this
miRNA (p = 0.02 and p = 0.03, respectively). No other statistically significant
correlations were observed between the analysed miRNAs and the main
clinico-pathological characteristics of the NSCLC patients. Conclusion: The
results indicated that miR-205 could represent a useful marker in the
prognostic management of the early-stage (T1N0) NSCLC patients.
Non-Small Cell Lung Cancer miR-21 let-7g miR-205 Prognosis1. Introduction
MicroRNAs (miRNAs) are short, non-coding RNAs of approximately 19 - 24 nucleotides in length, emerged for their ability to bind to the 3’-untranslated regions (UTRs) of messenger RNAs, where they interfere with trans- lation, and thereby regulate cell differentiation, apoptosis, and tumorigenesis. Since their initial discovery in 1993 [1] , several published data found that some of these miRNAs act as oncogenes, whereas others exhibit tu- mor suppressor properties [2] -[4] . Altered miRNA expression has been implicated in several carcinomas, in- cluding non-small cell lung cancer (NSCLC); moreover, aberrant expression of miRNAs is significantly related to tumor stage, suggesting that they could be potential markers for cancer prognosis [5] [6] .
Similar to breast cancer, let-7 is down regulated in NSCLC [7] -[9] . Several investigators have shown that let-7 harbors tumor suppressive properties both in vitro and in vivo [10] -[13] .
MiR-21 has been identified as the best hit in a number of high-through screen experiments designed for the detection of cancer related miRNAs [14] . The exact molecular mechanism of miR-21 elevation and its role in cancer development and progression is currently unclear. Interestingly, several miRNAs, including miR-205, seem to be differently involved in the pathogenesis of the two major NSCLC histologies, adenocarcinomas (ADCs) and squamous cell carcinomas (SCCs).
Moreover, recent published studies [15] -[18] have correlated miRNA expression with prognosis in lung can- cer, arising the possibility of using miRNA expression profiles to predict outcomes in NSCLC, especially in early stage lung cancer patients in order to identify those at high risk of relapse after surgical resection [19] .
The aim of this study was to evaluate let-7g, miR-21 and miR-205 expression in a series of 105 early-stage (T1N0) NSCLC patients to establish their potential prognostic value.
2. Patients and Methods2.1. Patients Selection
One hundred and five NSCLC cases were retrospectively selected from patients operated at the Unit of Thoracic Surgery of the A.O.U.P. between 2000 and 2010. Histological diagnoses were independently formulated by two pathologists (G.F. and G.A.) according to the World Health Organization classification [20] -[22] . Clinico-pa- thological characteristics and clinical data were collected for all the patients. All the patients gave their informed consent to the molecular analyses.
2.2. RNA Isolation
Total RNA including miRNAs was isolated from 5 - 10 μm sections of formalin-fixed and paraffin-embedded (FFPE) tissues after manual tumor macrodissection using the miRNeasy FFPE Kit (Qiagen), according to the manufacturer’s instructions.
2.3. miRNA Expression
Quantification of let-7g, miR-21, miR-205, and RNU6B expression was carried out in triplicate into 105 NSCLC and into a pool of 27 non-cancerous lung tissues using specific TaqMan® MicroRNA Assays (Applied Biosys- tems), according to the manufacturer’s instructions. Briefly, 10 ng of RNA were retro-transcribed by the Taq- Man® MicroRNA Reverse Transcription (RT) Kit (Applied Biosystems), and 1.3 μl of RT product were ana- lysed by quantitative Real Time-PCR (qRT-PCR) on the Rotor-Gene 6000 (Corbett Research).
Threshold cycle (Ct) and baselines were determined by manual settings. miRNA expression was calculated by relative quantification and fold expression changes were determined by the 2−ΔΔCt method using the DataAssistTM software (Applied Biosystems).
2.4. Statistical Analysis
One-way analysis of variance and χ2 test were used to determine the association between miRNA expression and the different parameters, while survival analysis was performed by the Kaplan-Meier method. Statistical analyses were performed using the JMP10 software (SAS) and a two-tailed p value <0.05 was considered significant.
3. Results3.1. Patient Characteristics
This study was conducted in 105 patients with early-stage NSCLC (T1N0), including 57 adenocarcinomas (ADCs), and 48 squamous cell carcinomas (SCCs). As regards histological classification, different histologic subtypes of adenocarcinoma were recognised: acinar (20/57, 35%), lepidic (18/57, 31.6%), mucinous (9/57, 15.8%), papillar (7/57, 12.3%), and solid (3/57, 5.3%) variants.
The median age at diagnosis was 67 years (range: 49 - 81) and the median follow up was 63 months (range: 6 - 161). Regarding grading, 5 tumors were G1, whereas 73 and 27 were G2 and G3, respectively. Disease pro- gression and death from lung cancer were observed in 27 (25.7%) and in 21 (20%) of the 105 NSCLC patients, respectively. The median progression-free survival (PFS) and overall survival (OS) were 58 months (95% CI: 6 - 161) and 69 months (95% CI: 11 - 161), respectively. Regarding smoking habits, there were 15 non-smokers, 45 former smokers, and 45 current smokers.
3.2. let-7g, miR-21, and miR-205 Expression Profile and Clinico-Pathological Characteristics
We quantified the mature let-7g, miR-21, and miR-205 expression normalized to the RNU6B endogenous con- trol in 105 NSCLC and in non-cancerous tissues. To determine whether miRNA profile was correlated with the main clinico-pathological characteristics, the NSCLC patients were divided into let-7g, miR-21, and miR-205 high and low expression groups based on median fold change values (0.451 for let-7g, 1.819 for miR-21, and 1.409 for miR-205). Except for a significant association between the low miR-205 expression and ADC histo- type (p < 0.0001) compared to SCC, no other statistically significant associations were observed between the analysed miRNAs and the main clinico-pathological characteristics of the NSCLC patients (Table 1).
3.3. Survival Analysis
To evaluate the relationships of let-7g, miR-21, and miR-205 expression with prognosis of the NSCLC patients,
Table 1
. Correlations between the expression of let-7g, miR-21, and miR-205 and the main clinico-pathological characte- ristics of the NSCLC patients
Characteristic
let-7g Expression
p
miR-21 Expression
p
miR-205 Expression
p
Low
High
Low
High
Low
High
Age
≤67 years
28 (52.8%)
25 (48.2%)
0.626
29 (54.7%)
24 (45.3%)
0.758
38 (71.7%)
15 (28.3%)
0.539
>67 years
25 (48.1%)
27 (51.9%)
30 (57.7%)
22 (42.3%)
40 (76.9%)
12 (23.1%)
Gender
Males
38 (50.7%)
37 (49.3%)
0.95
44 (58.7%)
31 (41.3%)
0.419
52 (69.3%)
23 (30.7%)
0.054
Females
15 (50%)
15 (50%)
15 (50%)
15 (50%)
26 (86.7%)
4 (13.3%)
Histology
ADC
28 (49.1%)
29 (50.9%)
0.762
33 (57.9%)
24 (42.1%)
0.701
55 (96.5%)
2 (3.5%)
<0.0001
SCC
25 (52.1%)
23 (47.9%)
26 (54.2%)
22 (45.8%)
23 (47.9%)
25 (52.1%)
Tumor grade
G1
4 (80%)
1 (20%)
0.171
4 (80%)
71 (20%)
0.516
5 (100%)
0 (0%)
G2
33 (45.2%)
40 (54.8%)
40 (54.8%)
33 (45.2%)
56 (76.7%)
17 (23.3%)
0.08
G3
16 (59.3%)
11 (40.7%)
15 (55.6%)
12 (44.4%)
17 (63%)
10 (37%)
Smoking
Never smoking
8 (53.3%)
7 (46.7%)
0.795
8 (53.3%)
7 (46.7%)
0.551
13 (86.7%)
2 (13.3%)
Former smoking
21 (46.7%)
24 (53.3%)
23 (51.1%)
22 (48.9%)
30 (66.7%)
15 (33.3%)
0.226
Current smoking
24 (53.3%)
21 (46.7%)
28 (62.2%)
17 (37.8%)
35 (77.8%)
10 (22.2%)
we performed a survival analysis by the Kaplan-Meier method using the disease recurrence and the overall post-operative survival as endpoints. Interestingly, we found that the tumors with a high miR-205 expression showed a significantly shorter mean PFS and OS compared to the patients with a low expression of this miRNA (p = 0.02 and p = 0.03, respectively) (Figure 1). We did not observe any significant difference in PFS and OS of the NSCLC patients with a high let-7g or miR-21 expression compared to the patients with a low expression of these miRNAs.
4. Discussion
NSCLC accounts for approximately 70% of all lung cancer-related deaths worldwide [23] , reflecting the need for a better understanding of the mechanisms that underlie lung carcinogenesis. The chance of cure with surgery in early NSCLC is compromised by almost a 30% risk of developing distant metastases, and adjunctive prog- nostic parameters are necessary to select patients for adjuvant systemic treatments. Previously unknown markers, such as noncoding RNA gene, may also lend insight into the biology of lung cancer. MicroRNAs are a class of short noncoding RNAs that modulate gene expression by targeting messenger RNAs and triggering either the repression of translation or RNA degradation [24] . miRNAs are involved in tissue differentiation during both normal development and carcinogenesis, and miRNA expression profiles have been seen as a promising new class of markers for tumor diagnosis and prognosis [25] -[27] .
This study was aimed to evaluate let-7g, miR-21, and miR-205 expression profile in early stage NSCLC pa- tients (T1N0), with particular reference to their role in prognosis. In our study, miR-205 evaluation has been shown to have a significant association with SCC histotype, as it has been previously reported [28] . Considering
Figure 1
Kaplan-Meier curves in the NSCLC patients with a different miR-205 expression
that specific therapies for NSCLC patients are selected depending on the histologic diagnosis, a clinical diagnos- tic assay based on the expression levels of miR-205 should provide an alternative tool of differential diagnosis, when routinary immunohistochemistry fails. As far as is concerned the clinico-pathological characteristics, we did not observed any significant correlation between the miRNAs expression and the clinico-pathological fea- tures, including age, gender, hystotype, tumor grade, smoking habit, and recurrences. In our cases, Kaplan- Meier survival estimates showed that the early stage NSCLC patients with high miR-205 had a poorer survival than the patients with low expression, either for progression-free survival or overall survival, suggesting that miR-205 could represent a useful marker in the prognostic management of the early-stage (T1N0) NSCLC pa- tients. No difference in the prognosis was found for let-7g and miR-21. Regarding the prognostic role of the analysed miRNAs, Takamizawa et al. [7] first reported low expression of let-7 family members was associated with shorter overall survival in NSCLC; on the contrary, the prognostic role of mature let-7 family members was further investigated, but there were no differences in overall survival between clusters of cases with varying let-7 expression [8] . Similarly, the association between miR-21 or miR-205 expression and NSCLC prognosis has been explored in several studies, but the results are controversial. While some studies showed that miR-21 or miR-205 overexpression was associated with poor NSCLC survival [14] [29] [30] , other studies indicated the converse or insignificant association [31] [32] . To explain discrepancies on the prognostic value of miRNAs in NSCLC, some issues should be addressed. Different kinds of samples are used to detect miRNAs including fro- zen tissues, formalin-fixed paraffin-embedded (FFPE) tissues, serum and sputum. Saito et al. reported that the results concerning the association of miR-21 expression and NSCLC prognosis from frozen tissues were in ap- parent contrast to those from FFPE tissues [33] . Therefore, the type of samples could influence the results, and an appropriate sample type should be determined to extract miRNAs. Moreover, published studies have used different cut-point for high vs. low miRNA expression, but a standard cut-off should be identified in order to correctly compare data. In view of these points, further investigations are necessary to have a systematic evalua- tion of miRNAs in the molecular characterization of the NSCLC patients.
5. Conclusion
Based on our results, miRNA 205 expression may represent a useful marker in prognostic management of the early-stage (T1N0) NSCLC patients.
Financial Disclosure
This work was supported by Grant PRIN 20092009LMEEEH_004 from the Italian Ministry for University and Scientific Research. The authors declared no conflict of interests.
ReferencesLEE R.C., FEINBAUM R.L. , AMBROS V. ,et al. (1993)THE C. ELEGANS HETEROCHRONIC GENE LIN-4 ENCODES SMALL RNAS WITH ANTISENSE COMPLEMENTARITY TO LIN-14 75, 843-854.HTTP://DX.DOI.ORG/10.1016/0092-8674(93)90529-YAMBROS V., BARTEL B., BARTEL D.P., BURGE C.B., CARRINGTON J.C., CHEN X., DREYFUSS G., EDDY S.R., GRIFFITHS-JONES S., MARSHALL M., MATZKE M., RUVKUN G. , TUSCHL T. ,et al. (2003)A UNIFORM SYSTEM FOR MICRORNA ANNOTATION 9, 277-279.HTTP://DX.DOI.ORG/10.1261/RNA.2183803CHEN C.Z. ,et al. (2005)MICRORNAS AS ONCOGENES AND TUMOR SUPPRESSORS 353, 1768-1771.HTTP://DX.DOI.ORG/10.1056/NEJMP058190CALIN G.A. , CROCE C.M. ,et al. (2006)MICRORNA-CANCER CONNECTION: THE BEGINNING OF A NEW TALE 66, 7390-7394.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-06-0800FERRACIN M., VERONESE A. , NEGRINI M. ,et al. (2010)MICROMARKERS: MIRNAS IN CANCER DIAGNOSIS AND PROGNOSIS 10, 297-308.HTTP://DX.DOI.ORG/10.1586/ERM.10.11NANA-SINKAM S.P., FABBRI M. , CROCE C.M. ,et al. (2010)MICRORNAS IN CANCER: PERSONALIZING DIAGNOSIS AND THERAPY 1210, 25-33.HTTP://DX.DOI.ORG/10.1111/J.1749-6632.2010.05822.XTAKAMIZAWA J., KONISHI H., YANAGISAWA K., TOMIDA S., OSADA H., ENDOH H., HARANO T., YATABE Y., NAGINO M., NIMURA Y., MITSUDOMI T. , TAKAHASHI T. ,et al. (2004)REDUCED EXPRESSION OF THE LET-7 MICRORNAS IN HUMAN LUNG CANCERS IN ASSOCIATION WITH SHORTENED POSTOPERATIVE SURVIVAL 64, 3753-3756.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-04-0637INAMURA K., TOGASHI Y., NOMURA K., NINOMIYA H., HIRAMATSU M., SATOH Y., OKUMURA S., NAKAGAWA K. , ISHIKAWA Y. ,et al. (2007)LET-7 MICRORNA EXPRESSION IS REDUCED IN BRONCHIOLOALVEOLAR CARCINOMA, A NONINVASIVECARCINOMA, AND IS NOT CORRELATED WITH PROGNOSIS 58, 392-396.HTTP://DX.DOI.ORG/10.1016/J.LUNGCAN.2007.07.013NICOLOSO M., SPIZZO R., SHIMIZU M., ROSSI S. , CALIN G. ,et al. (2009)MICRORNAS-THEMICRO STEERING WHEEL OF TUMOUR METASTASES 9, 293-302.HTTP://DX.DOI.ORG/10.1038/NRC2619JOHNSON C.D., ESQUELA-KERSCHER A., STEFANI G., BYROM M., KELNAR K., OVCHARENKO D., WILSON M., WANG X., SHELTON J., SHINGARA J., CHIN L., BROWN D. , SLACK F.J. ,et al. (2007)THE LET-7 MICRORNA REPRESSES CELL PROLIFERATION PATHWAYS IN HUMAN CELLS 67, 7713-7722.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-07-1083KUMAR M.S., ERKEL, S.J. PESTER, R.E. CHEN, C.Y. EBERT, M.S. SHARP, P.A. JACKS, T. ,et al. (2008)SUPPRESSION OF NON-SMALL CELL LUNG TUMOR DEVELOPMENT BY THE LET-7 MICRORNA FAMILY 105, 3903-3908.HTTP://DX.DOI.ORG/10.1073/PNAS.0712321105TRANG P., MEDINA P., WIGGINS J., RUFFINO L., KELNAR K., OMOTOLA M., HOMER R., BROWN D., BADER A.G., WEIDHAAS J.B. , SLACK F.J. ,et al. (2009)REGRESSION OF MURINE LUNG TUMORS BY THE LET-7 MICRORNA 29, 1580-1587.HTTP://DX.DOI.ORG/10.1038/ONC.2009.445TRANG P., WIGGINS J., DAIGE C., CHO C., OMOTOLA M., BROWN D., WEIDHAAS J.B., BADER A.G. , SLACK F.J. ,et al. (2011)SYSTEMIC DELIVERY OF TUMOR SUPPRESSOR MICRORNA MIMICS USING A NEUTRAL LIPID EMULSION INHIBITS LUNGTUMORS IN MICE 19, 1116-1122.HTTP://DX.DOI.ORG/10.1038/MT.2011.48GAO W., YU Y., CAO H., SHEN H., LI X., PAN S. , SHU Y. ,et al. (2010)DEREGULATED EXPRESSION OF MIR-21, MIR-143 AND MIR-181A IN NON SMALL CELL LUNG CANCER IS RELATED TO CLINICOPATHOLOGIC CHARACTERISTICS OR PATIENT PROGNOSIS 64, 399-408.HTTP://DX.DOI.ORG/10.1016/J.BIOPHA.2010.01.018YANAIHARA N., CAPLEN N., BOWMAN E., SEIKE M., KUMAMOTO K., YI M., STEPHENS R.M., OKAMOTO A., YOKOTA J., TANAKA T., CALIN G.A., LIU C.G., CROCE C.M. , HARRIS C.C. ,et al. (2006)UNIQUE MICRORNA MOLECULAR PROFILES IN LUNG CANCER DIAGNOSIS AND PROGNOSIS 9, 189-198.HTTP://DX.DOI.ORG/10.1016/J.CCR.2006.01.025RAPONI M., DOSSEY L., JATKOE T., WU X., CHEN G., FAN H. , BEER D.G. ,et al. (2009)MICRORNA CLASSIFIERS FOR PREDICTING PROGNOSIS OF SQUAMOUS CELL LUNG CANCER 69, 5776-5783.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-09-0587LI, M.T. ZHAO, Y. ROTUNNO, M. KOSHIOL, J. LIU, H. BERGEN, A.W. RUBAGOTTI, M. GOLDSTEIN, A.M. LINNOILA, I. MARINCOLA, F.M. TUCKER, M.A. BERTAZZI, P.A. PESATORI, A.C. CAPORASO, N.E. MCSHANE, L.M. WANG, E. ,et al. (2010)MICRORNA EXPRESSION DIFFERENTIATES HISTOLOGY AND PREDICTS SURVIVAL OF LUNG CANCER 16, 430-441.HTTP://DX.DOI.ORG/10.1158/1078-0432.CCR-09-1736PATNAIK S.K., KANNISTO E., KNUDSEN S. , YENDAMURI S. ,et al. (2010)EVALUATION OF MICRORNA EXPRESSION PROFILES THAT MAY PREDICT RECURRENCE OF LOCALIZED STAGE I NON-SMALL CELL LUNG CANCER AFTER SURGICAL RESECTION 70, 36-45.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-09-3153LU Y., GOVINDAN R., WANG L., LIU P.Y., GOODGAME B., WEN W., SEZHIYAN A., PFEIFER J., LI Y.F., HUA X., WANG Y., YANG P. , YOU M. ,et al. (2012)MICRORNA PROFILING AND PREDICTION OF RECURRENCE/RELAPSE-FREE SURVIVAL IN STAGE I LUNG CANCER 33, 1046-1054.HTTP://DX.DOI.ORG/10.1093/CARCIN/BGS100TRAVIS, W.D., BRAMBILLA, E., MULLER-HEMERLINK, H.K. AND HARRIS, C.C. (2004) WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMOURS. PATHOLOGY AND GENETICS OF TUMOURS OF THE LUNG, PLEURA, THYMUS AND HEART. IARC PRESS, LYON.TRAVIS W.D., BRAMBILLA E., NOGUCHI M., NICHOLSON A.G., GEISINGER K.R., YATABE Y., BEER D.G., POWELL C.A., RIELY G.J., VAN SCHIL P.E., GARG K., AUSTIN J.H., ASAMURA H., RUSCH V.W., HIRSCH F.R., SCAGLIOTTI G., MITSUDOMI T., HUBER R.M., ISHIKAWA Y., JETT J., SANCHEZ-CESPEDES M., SCULIER J.P., TAKAHASHI T., TSUBOI M., VANSTEENKISTE J., WISTUBA I., YANG P.C., ABERLE D., BRAMBILLA C., FLIEDER D., FRANKLIN W., GAZDAR A., GOULD M., HASLETON P., HENDERSON D., JOHNSON B., JOHNSON D., KERR K., KURIYAMA K., LEE J.S., MILLER V.A., PETERSEN I., ROGGLI V., ROSELL R., SAIJO N., THUNNISSEN E., TSAO M. , YANKELEWITZ D. ,et al. (2011)INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER/AMERICAN THORACIC SOCIETY/EUROPEAN RESPIRATORY SOCIETY INTERNATIONAL MULTIDISCIPLINARY CLASSIFICATION OF LUNG ADENOCARCINOMA 6, 244-285.HTTP://DX.DOI.ORG/10.1097/JTO.0B013E318206A221TRAVIS W.D., BRAMBILLA E., NOGUCHI M., NICHOLSON A., GEISINGER K., YATABE Y., ISHIKAWA Y., WISTUBA I., FLIEDER D.B., FRANKLIN W., GAZDAR A., HASLETON P.S., HENDERSON D.W., KERR K.M., PETERSEN I., ROGGLI V., THUNNISSEN E. , TSAO M. ,et al. (2013)DIAGNOSIS OF LUNG CANCER IN SMALL BIOPSIES AND CYTOLOGY: IMPLICATIONS OF THE 2011 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER/AMERICAN THORACIC SOCIETY/EUROPEAN RESPIRATORY SOCIETY CLASSIFICATION 137, 668-684.HTTP://DX.DOI.ORG/10.5858/ARPA.2012-0263-RASIEGEL R., NAISHADHAM D. , JEMAL A. ,et al. (2012)CANCER STATISTICS, 2012 62, 10-29.HTTP://DX.DOI.ORG/10.3322/CAAC.20138BARTEL D.P. ,et al. (2004)MICRORNAS: GENOMICS, BIOGENESIS, MECHANISM, AND FUNCTION 116, 281-297.HTTP://DX.DOI.ORG/10.1016/S0092-8674(04)00045-5MASCAUX C., LAES J.F., ANTHOINE G., HALLER A., NINANE V., BURNY A. , SCULIER J.P. ,et al. (2009)EVOLUTION OF MICRO-RNA EXPRESSION DURING HUMAN BRONCHIAL SQUAMOUS CARCINOGENESIS 33, 352-359.HTTP://DX.DOI.ORG/10.1183/09031936.00084108IORIO M.V. , CROCE C.M. ,et al. (2009)MICRORNAS IN CANCER: SMALL MOLECULES WITH A HUGE IMPACT 27, 5848-5856.HTTP://DX.DOI.ORG/10.1200/JCO.2009.24.0317LU J., GETZ G., MISKA E.A., ALVAREZ-SAAVEDRA E., LAMB J., PECK D., SWEET-CORDERO A., EBERT B.L., MAK R.H., FERRO, A.A. DOWNING, J.R. JACKS, T. HORVITZ, H.R. GOLUB, T.R. ,et al. (2005)MICRORNA EXPRESSION PROFILES CLASSIFY HUMAN CANCERS 435, 834-838.HTTP://DX.DOI.ORG/10.1038/NATURE03702LEBANONY D., BENJAMIN H., GILAD S., EZAGOURI M., DOV A., ASHKENAZI K., GEFEN N., IZRAELI S., RECHAVI G., PASS H., NONAKA D., LI J., SPECTOR Y., ROSENFELD N., CHAJUT A., COHEN D., AHARONOV R. , MANSUKHANI M. ,et al. (2009)DIAGNOSTIC ASSAY BASED ON HSA-MIR-205 EXPRESSION DISTINGUISHES SQUAMOUS FROM NONSQUAMOUS NON-SMALL-CELL LUNG CARCINOMA 27, 2030-2037.HTTP://DX.DOI.ORG/10.1200/JCO.2008.19.4134LIU X.G., ZHU W.Y., HUANG Y.Y., MA L.N., ZHOU S.Q., WANG Y.K., ZENG F., ZHOU J.H. , ZHANG Y.K. ,et al. (2012)HIGH EXPRESSION OF SERUM MIR-21 AND TUMOR MIR-200C ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH LUNG CANCER 29, 618-626.HTTP://DX.DOI.ORG/10.1007/S12032-011-9923-YGAO W., SHEN H., LUI L., XU J., XU J. , SHU Y. ,et al. (2011)MIR-21 OVEREXPRESSION IN HUMAN PRIMARY SQUAMOUS CELL LUNG CARCINOMA IS ASSOCIATED WITH POOR PATIENT PROGNOSIS 137, 557-566.HTTP://DX.DOI.ORG/10.1007/S00432-010-0918-4MARKOU A., TSAROUCHA E.G., KAKLAMANIS L., KAKLAMANIS L., FOTINOU M., GEORGOULIAS V. , LIANIDOU E.S. ,et al. (2008)PROGNOSTIC VALUE OF MATURE MICRORNA-21 AND MICRORNA-205 OVEREXPRESSION IN NON-SMALL CELL LUNG CANCER BY QUANTITATIVE REAL-TIME RT-PCR 54, 1696-1704.HTTP://DX.DOI.ORG/10.1373/CLINCHEM.2007.101741VOORTMAN J., GOTO A., MENDIBOURE J., SOHN J.J., SCHETTER A.J., SAITO M., DUNANT A., PHAM T.C., PETRINI I., LEE A., KHAN M.A., HAINAUT P., PIGNON J.P., BRAMBILLA E., POPPER H.H., FILIPITS M., HARRIS C.C. , GIACCONE G. ,et al. (2010)MICRORNA EXPRESSION AND CLINICAL OUTCOMES IN PATIENTS TREATED WITH ADJUVANT CHEMOTHERAPY AFTER COMPLETE RESECTION OF NON-SMALL CELL LUNG CARCINOMA 70, 8288-8298.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-10-1348SAITO M., SCHETTER A.J., MOLLERUP S., KOHNO T., SKAUG V., BOWMAN E.D., MATHÉ E.A., TAKENOSHITA S., YOKOTA J., HAUGEN A. , HARRIS C.C. ,et al. (2011)THE ASSOCIATION OF MICRORNA EXPRESSION WITH PROGNOSIS AND PROGRESSION IN EARLY-STAGE, NON-SMALL CELLLUNG ADENOCARCINOMA: A RETROSPECTIVE ANALYSIS OF THREE COHORTS 17, 1875-1882.HTTP://DX.DOI.ORG/10.1158/1078-0432.CCR-10-2961